Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal.

Conclusions: Our findings indicate that screening for LTBI should be more frequent in patients from high tuberculosis burden countries; treatment of LTBI with rifampicin/isoniazid combination for 3 months is effective in preventing reactivation even when adalimumab is started simultaneously. PMID: 31057626 [PubMed]
Source: International Journal of Rheumatology - Category: Rheumatology Tags: Int J Rheumatol Source Type: research